Deborah A Thomas

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia
    Ahmed Aribi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 109:1355-9. 2007
  2. ncbi request reprint Current role of thalidomide in cancer treatment
    D A Thomas
    University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston 77030, USA
    Curr Opin Oncol 12:564-73. 2000
  3. pmc Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6330-7. 2009
  4. ncbi request reprint Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
  5. ncbi request reprint Thalidomide therapy for myelofibrosis with myeloid metaplasia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1974-84. 2006
  6. ncbi request reprint New agents in the treatment of acute lymphocytic leukaemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX, 77030, USA
    Best Pract Res Clin Haematol 15:771-90. 2002
  7. ncbi request reprint Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:120-7. 2006
  8. ncbi request reprint Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 104:1624-30. 2004
  9. ncbi request reprint Rituximab in relapsed or refractory hairy cell leukemia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:3906-11. 2003
  10. ncbi request reprint Monoclonal antibody therapy for hairy cell leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, 77030, USA
    Hematol Oncol Clin North Am 20:1125-36. 2006

Detail Information

Publications90

  1. ncbi request reprint Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia
    Ahmed Aribi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 109:1355-9. 2007
    ..Arsenic trioxide (ATO) is an effective agent for the salvage of patients with recurrent APL, and gemtuzumab ozogamicin (GO) has shown activity in patients with APL...
  2. ncbi request reprint Current role of thalidomide in cancer treatment
    D A Thomas
    University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston 77030, USA
    Curr Opin Oncol 12:564-73. 2000
    ..A summary of the preliminary results of ongoing clinical trials is presented, and the future directions of thalidomide research in the oncology are discussed...
  3. pmc Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6330-7. 2009
    ..Incorporation of monoclonal antibodies directed against CD20 into frontline chemotherapy regimens warrants investigation...
  4. ncbi request reprint Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
    ..Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed...
  5. ncbi request reprint Thalidomide therapy for myelofibrosis with myeloid metaplasia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1974-84. 2006
    ..Thalidomide is a putative antiangiogenesis agent with activity in several hematologic malignancies...
  6. ncbi request reprint New agents in the treatment of acute lymphocytic leukaemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX, 77030, USA
    Best Pract Res Clin Haematol 15:771-90. 2002
    ..An increasing number of unique active new chemotherapeutic and biological agents are available for study. This chapter reviews new agents with the potential to be incorporated into therapeutic strategies for the treatment of ALL...
  7. ncbi request reprint Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:120-7. 2006
    ..Vincristine is an important component of ALL therapy. In animal models, the encapsulation of vincristine into sphingomyelin liposomes or "sphingosomes" for injection (SV) has improved efficacy compared with conventional vincristine...
  8. ncbi request reprint Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 104:1624-30. 2004
    ..Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease...
  9. ncbi request reprint Rituximab in relapsed or refractory hairy cell leukemia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 102:3906-11. 2003
    ..Rituximab has significant activity and minimal toxicity in HCL and warrants further study. Rituximab should be explored further in HCL with regard to eradication of minimal residual disease and in combination with nucleoside analogs...
  10. ncbi request reprint Monoclonal antibody therapy for hairy cell leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, 77030, USA
    Hematol Oncol Clin North Am 20:1125-36. 2006
    ..Appropriate pharmacologic investigation, use of antigen modulation, and assessments of soluble antigen levels should be considered with future clinical trial s of MoAb's in HCL to optimize therapeutic strategies...
  11. ncbi request reprint Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia
    Deborah A Thomas
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Br J Haematol 123:436-41. 2003
    ..Thalidomide analogues with more potent immunomodulatory activities and more favourable toxicity profiles may offer more promise as anti-AML therapy...
  12. ncbi request reprint Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:5490-8. 2009
    ..Vincristine (VCR) sulfate liposomes injection (VSLI) is a sphingomyelin/cholesterol nanoparticle encapsulated VCR formulation that improves the pharmacokinetic profile of VCR without augmenting neurotoxicity...
  13. doi request reprint New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia
    Deborah A Thomas
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Hematol Malig Rep 2:183-9. 2007
    ..Optimal use of these novel agents in the treatment schema of Ph-positive ALL will be paramount in ensuring continued success in the eradication of this disease...
  14. ncbi request reprint Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 23:949-71, v. 2009
    ..Preliminary data regarding the use of rituximab in frontline therapy for CD20- positive precursor B-cell ALL suggest its use may also be beneficial, particularly for the younger subsets...
  15. ncbi request reprint Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 50:27-31. 2009
    ..Herein, the available data regarding the prevalence and clinical relevance of MRD after therapy for HCL is reviewed...
  16. ncbi request reprint Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen
    Deborah Thomas
    Department of Leukemia, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4580-9. 2010
    ..5 g/m2 IV on Days 1 and 2) to the standard hyper-CVAD regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and cytarabine) would improve outcome...
  17. pmc Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
    Deborah A Thomas
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3880-9. 2010
    ....
  18. ncbi request reprint Lymphoblastic lymphoma
    D A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Hematol Oncol Clin North Am 15:51-95, vi. 2001
    ..Improved outcome with the newer intensive chemotherapy regimens and the role of modalities such as autologous intensification, allogeneic bone marrow transplant, and radiotherapy are discussed...
  19. doi request reprint Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?
    Deborah A Thomas
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Curr Hematol Malig Rep 6:58-66. 2011
    ..This review presents a comprehensive overview of the previously designated provisional entity of atypical BL/BLL in conjunction with a detailed comparison with BL and DLBCL...
  20. ncbi request reprint Antiangiogenic therapy in leukemia
    D A Thomas
    Department of Leukemia, M D Anderson Cancer Center, Houston, Tex 77030, USA
    Acta Haematol 106:190-207. 2001
    ..The role of angiogenesis in hematological malignancies, the rationale for the use of angiosuppressive therapy for these entities, and the status of novel antiangiogenic agents in clinical trials are discussed...
  21. pmc Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
    Farhad Ravandi
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 122:1214-21. 2013
    ..2). At 3 and 12 months, negative MRD by MFC was associated with improved survival (P = .04 and .001). MRD monitoring by PCR and MFC identifies patients who benefit from treatment intensification in first CR...
  22. ncbi request reprint Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
    ..Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens...
  23. ncbi request reprint Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 52:449-52. 2003
    ..The Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen was evaluated in patients in complete remission following Mylotarg-containing regimens...
  24. pmc A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
    Elias Jabbour
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1236-44. 2011
    ..The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome...
  25. ncbi request reprint Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Blood 101:3413-5. 2003
    ..The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses...
  26. ncbi request reprint Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:1722-7. 2003
    ..A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy...
  27. ncbi request reprint Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:1287-92. 2004
    ....
  28. ncbi request reprint Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
    Jorge E Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:3794-800. 2003
    ..The 3-month cytogenetic response to imatinib mesylate refined the prognostic relevance of such studies in patients on imatinib mesylate therapy...
  29. ncbi request reprint Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3547-53. 2002
    ..04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML...
  30. ncbi request reprint Eradication of minimal residual disease in hairy cell leukemia
    Farhad Ravandi
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:4658-62. 2006
    ..Disease characteristics may potentially be used to identify patients that are more likely to benefit from such additional therapy...
  31. ncbi request reprint Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 100:1590-5. 2002
    ..We conclude that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD...
  32. ncbi request reprint Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2167-76. 2002
    ..Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML)...
  33. ncbi request reprint Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
    Apostolia M Tsimberidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1711-20. 2003
    ..A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) in these patients...
  34. pmc Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
    Constantine S Tam
    Departments ofLeukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:975-80. 2008
    ..5% per year for the third year onward. In a multivariate analysis of patients receiving fludarabine-based therapy at our center, FCR therapy emerged as the strongest independent determinant of survival...
  35. ncbi request reprint A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:1638-45. 2008
    ..4 months vs 5.8 months; P = .1). Clofarabine plus low-dose cytarabine has a higher response rate than clofarabine alone with comparable toxicity. This trial is registered at www.clinicaltrials.gov as no. NCT00088218...
  36. ncbi request reprint Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
    Susan M O'Brien
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2657-63. 2003
    ..The objective of this study was to investigate the efficacy and safety of alemtuzumab, the humanized anti-CD52 monoclonal antibody, in patients with B-cell chronic lymphocytic leukemia and residual disease after chemotherapy...
  37. ncbi request reprint Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2177-87. 2002
    ..We identified pretreatment and treatment-associated factors that were associated with higher major cytogenetic response rates and with improved survival...
  38. ncbi request reprint Phase II study of alemtuzumab in chronic lymphoproliferative disorders
    Alessandra Ferrajoli
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:773-8. 2003
    ..Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders...
  39. ncbi request reprint Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 109:3214-8. 2007
    ..Liposomal cytarabine given via intrathecal route concomitantly with systemic chemotherapy that crosses the blood-brain barrier such as high-dose MTX and cytarabine can result in significant neurotoxicity...
  40. ncbi request reprint Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:1050-6. 2003
    ..Troxacitabine has significant single-agent activity. This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan...
  41. doi request reprint Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Constantine S Tam
    Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:5587-93. 2009
    ..We aimed to define an accelerated phase (AP) in MF by characterizing disease features that can identify patients with median overall survival of <or= 12 months at any time in the disease course...
  42. ncbi request reprint Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen
    Mary Ann Weiser
    Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1179-85. 2004
    ....
  43. ncbi request reprint Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
    Elihu H Estey
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:4343-9. 2002
    ..Thus, there is little evidence to suggest that GO with or without IL-11 should be used instead of IA in older patients with newly diagnosed AML or myelodysplastic syndrome...
  44. ncbi request reprint Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia
    Sergej Konoplev
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Cancer 117:4689-95. 2011
    ..Data regarding the prognostic impact of CXCR4 in patients with B-acute lymphoblastic leukemia (B-ALL) are sparse and limited to the pediatric population...
  45. pmc Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial
    Maria E Cabanillas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:848-55. 2012
    ....
  46. ncbi request reprint The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma
    Bouthaina S Dabaja
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Box 97, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 94:2738-44. 2002
    ..The objective of this study was to investigate the role of mediastinal radiation therapy in patients who achieve a complete response (CR) to chemotherapy...
  47. doi request reprint The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
    Constantine S Tam
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:4171-8. 2009
    ..Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prospectively evaluated...
  48. ncbi request reprint Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2134-41. 2002
    ....
  49. ncbi request reprint Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia
    Susan O'Brien
    Division of Cancer Medicine, Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2097-101. 2008
    ..Understanding the causes of failure in older patients with acute lymphocytic leukemia (ALL) may help improve treatment strategies for patients in this particular age group...
  50. ncbi request reprint A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Zhuang Zuo
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Mod Pathol 23:1524-34. 2010
    ..This unique 9-gene signature may better enable stratification of patients to proper therapeutic regimens and provides new insights into mechanisms of Ph+ ALL response to therapy...
  51. ncbi request reprint Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 100:1449-58. 2004
    ..OSI-211 is a low-clearance, unilamellar liposomal formulation of a water-soluble camptothecin analogue, lurtotecan. OSI-211 has significant activity in severe combined immunodeficient mouse models of human leukemia...
  52. pmc A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia
    Khanh Vu
    Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 12:355-62. 2012
    ..conventional therapy. Intensive insulin did not improve ALL clinical outcomes despite improved glycemic control. Secondary analysis suggests that the choice of antidiabetic pharmacotherapy may influence ALL outcomes...
  53. pmc Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?
    Guilin Tang
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Haematologica 97:919-25. 2012
    ..Precursor B-acute lymphoblastic leukemia occurring in patients with a history of malignancies is uncommon, and this condition is not well understood...
  54. ncbi request reprint Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors
    Gautam Borthakur
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 136:800-5. 2007
    ..Thus, the incidence of IA among CLL patients treated with FCR was comparable with historical rates. The diagnosis of AIHA can be considered even if the DAT is negative. Pre-existing AIHA need not preclude front-line FCR therapy...
  55. ncbi request reprint Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Box 428, Houston, TX 77030, USA
    Leuk Res 27:1077-83. 2003
    ..Based on these clinical, pharmacokinetic, and pharmacodynamic data, Triapine warrants further study in patients with hematologic malignancies...
  56. pmc Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth
    Hongbo Lu
    Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Hematol 93:485-92. 2014
    ..Data suggest that CTGF represents a targetable molecular aberration in B-ALL, and blocking CTGF signaling in conjunction with administration of chemotherapy may represent a novel therapeutic approach for ALL patients. ..
  57. ncbi request reprint Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
    Srdan Verstovsek
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 120:1202-9. 2012
    ....
  58. ncbi request reprint Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Fabio P S Santos
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 115:1131-6. 2010
    ..In conclusion, CEP-701 resulted in modest efficacy and mild but frequent gastrointestinal toxicity in MF patients. The study was registered at http://clinicaltrials.gov as NCT00494585...
  59. ncbi request reprint Phase I study of oral topotecan in hematological malignancies
    Miloslav Beran
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:4084-91. 2003
    ..In this Phase I, dose-seeking study, we investigated the dose-limiting toxicities (DLTs) and maximal tolerated dose (MTD) of oral topotecan in patients with hematological malignancies...
  60. ncbi request reprint Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia
    Stefan Faderl
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Blood 106:4303-7. 2005
    ..These data reflect the complexity by which angiogenic factors may affect the clinical behavior of patients with ALL, and this complexity should be considered in any therapeutic strategy incorporating antiangiogenic agents...
  61. ncbi request reprint Salvage therapy for refractory or relapsed acute lymphocytic leukemia
    G Garcia-Manero
    Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Hematol Oncol Clin North Am 15:163-205. 2001
    ..Attainment of a second or later CR should be followed by allogeneic BMT when feasible owing to the paucity of long-term survivors with salvage chemotherapy alone...
  62. ncbi request reprint Philadelphia-positive acute lymphoblastic leukemia: current treatment options
    Theresa Liu-Dumlao
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX, 77007, USA
    Curr Oncol Rep 14:387-94. 2012
    ..Additional strategies have also included incorporation of TKIs in the post-transplant setting and the use of newer third generation TKIs. This review provides an update on emerging therapies for adults with Ph-positive ALL...
  63. ncbi request reprint The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia
    Alessandra Ferrajoli
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:1215-9. 2002
    ..005). We conclude that the TNF-alpha level serves as a prognostic factor in patients with CLL and that inhibition of TNF-alpha in these patients could have therapeutic importance...
  64. ncbi request reprint Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen
    Mary A Weiser
    Department of General Internal Medicine, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 94:285-91. 2002
    ....
  65. ncbi request reprint Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome
    Hesham M Amin
    Department of Hematopathology, Box 72, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:1866-8. 2003
    ..Our findings suggest that the alterations in B lymphocytes in the form of increased apoptosis can be seen in MDS and support the concept that immune modulation plays a role in the pathophysiology of MDS...
  66. doi request reprint Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors
    Jesse Jaso
    Department of Pathology, The University of Texas Medical Center Health Sciences Center, Houston, Texas, USA
    Cancer 117:4009-17. 2011
    ..The prognostic significance of these parameters was assessed in the context of intensive tyrosine kinase inhibitor (TKI)-based chemotherapy...
  67. ncbi request reprint Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting
    Razelle Kurzrock
    Department of Bioimmunotherapy, Unit 422, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:4527-34. 2003
    ..09). We conclude that, at doses that are well tolerated, R115777 markedly inhibits the FTase target and has antitumor activity in MDS...
  68. ncbi request reprint A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia
    Tapan M Kadia
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 150:72-82. 2010
    ..The combination of vorinostat and idarubicin is generally tolerable and active in patients with advanced leukaemia and should be studied in the front-line setting...
  69. ncbi request reprint Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
    Iman Jilani
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 102:3514-20. 2003
    ..The importance of this down-modulation in the efficacy of current therapy with rituximab needs further investigation...
  70. ncbi request reprint Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Rev Clin Exp Hematol 6:142-60; discussion 200-2. 2002
    ..An overview of current treatment modalities in Ph-positive ALL will be provided and the rationale for new therapies will be discussed...
  71. ncbi request reprint Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
    Francis J Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:656-64. 2002
    ..To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia...
  72. ncbi request reprint Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival
    Francis J Giles
    Department of Leukaemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 119:38-45. 2002
    ..0002, Cox proportional hazard model). A multivariate model based on Cox-2 and degree of splenomegaly was developed for survival in patients with early CP CML. Agents that inhibit Cox-2 activity merit investigation in patients with CP CML...
  73. pmc The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
    Constantine S Tam
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:1628-37. 2008
    ..Myeloproliferative neoplasm blast phase is associated with a dismal prognosis. Responses to chemotherapy can be achieved but are not durable. Long-term survivors had all received SCT either as first therapy or in first remission...
  74. doi request reprint Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
    Srdan Verstovsek
    M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 363:1117-27. 2010
    ..INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor...
  75. doi request reprint Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia
    Alessandra Ferrajoli
    The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas, USA
    Cancer 117:3182-6. 2011
    ..In CLL, elevated serum β-2 microglobulin (β2M) levels were associated with more rapid disease progression and shorter survival (OS)...
  76. ncbi request reprint Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience
    A M Tsimberidou
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 16:139-45. 2005
    ..Recombinant interleukin (IL)-11 is a thrombopoietic growth factor. The purpose of this study was to assess the toxicity, safety and efficacy of low-dose recombinant IL-11 in patients with bone marrow failure (BMF)...
  77. ncbi request reprint Pilot study of low-dose interleukin-11 in patients with bone marrow failure
    R Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:4165-72. 2001
    ..Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates postchemotherapy thrombocytopenia at doses of 50 microg/kg/d subcutaneously. Very little is known about the activity of IL-11 in patients with bone marrow failure states...
  78. ncbi request reprint High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens
    M Beran
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 92:1999-2015. 2001
    ..Because the results of standard regimens have been disappointing, high-dose chemotherapeutic regimens were investigated recently. In the absence of randomized trials, the relative merits of various treatment regimens are unknown...
  79. ncbi request reprint Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation
    F J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 92:406-13. 2001
    ..Hepatic venoocclusive disease (VOD) has been reported in patients who have undergone stem cell transplantation (SCT) after Mylotarg therapy. Outside of the SCT setting, VOD has been associated very rarely with cytotoxic therapy...
  80. ncbi request reprint New approaches in the treatment of myelofibrosis
    Bryan T Hennessy
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:32-43. 2005
    ..g., thalidomide), tyrosine kinase inhibitors (e.g., imatinib mesylate), farnesyl transferase inhibitors (e.g., R115777), and other agents are reviewed, in addition to the potential roles of autologous and allogeneic SCT...
  81. ncbi request reprint Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy
    A M Tsimberidou
    Department of Leukemia, The University of Texas, MD Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Leukemia 17:1100-3. 2003
    ..The median survival of patients with chromosome 8 abnormalities was 12 months compared with 40 months of those without (P=0.17). Novel therapies for patients with GS are required...
  82. ncbi request reprint Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia
    F J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    J Clin Oncol 19:762-71. 2001
    ..To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia...
  83. ncbi request reprint Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer
    H T See
    Department of Gynecological Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Cancer 16:236-40. 2006
    ..The incidence and outcome of secondary leukemia in the setting of active ovarian carcinoma is reviewed...
  84. ncbi request reprint Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry
    Tariq Muzzafar
    Dept of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Pathol 132:692-8. 2009
    ..Decreased CD81 expression is a sensitive and specific marker for residual pre-B-ALL, even in a background of hematogones, making CD81 a useful addition to a panel for MRD detection by FC...
  85. ncbi request reprint Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:1920-8. 2003
    ..SU5416 is a small-molecule RTK inhibitor (RTKI) that targets VEGFR-2, c-kit, and fms-related tyrosine kinase Flk2...
  86. ncbi request reprint Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia
    Dawn E Colburn
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Invest New Drugs 21:109-11. 2003
    ..A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted...
  87. ncbi request reprint Rituximab dose-escalation trial in chronic lymphocytic leukemia
    H Kantarjian
    Leukemia Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:2165-70. 2001
    ..Efficacy of rituximab was also significant in this group of patients...
  88. ncbi request reprint Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome
    B S Dabaja
    Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, Texas 77030, USA
    Leuk Lymphoma 42:329-37. 2001
    ..0017). In conclusion the hyper CVXD regimen has a relatively high response rate, significant toxicity and a moderate impact on survival in RS...
  89. ncbi request reprint Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
    Edwin DeJesus
    IDC Research Initiative, Altamonte Springs, FL, USA
    Clin Infect Dis 39:411-8. 2004
    ..Median increase above baseline in CD4(+) cell count was similar (q.d. group, +144 cells/mm(3); b.i.d. group, +146 cells/mm(3)), and the incidences of adverse events, disease progression, and HIV-associated conditions were comparable...
  90. ncbi request reprint HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients
    Judith Falloon
    Laboratory of Immunoregulation, NIAID, National Institutes of Health, Building 10 Room 11C103, 10 Center Drive, Bethesda, MD 20892 1880, USA
    AIDS 16:387-96. 2002
    ..To assess the safety and efficacy of three new drugs in patients with antiretroviral failure and to correlate retrospectively baseline factors with virological response...